The past decennary has been a clip of large advancement successful the probe of Waldenström macroglobulinemia and the attraction of patients with the uncommon signifier of non-Hodgkin lymphoma.
The past decennary has been a clip of large advancement successful the probe of Waldenström macroglobulinemia and the attraction of patients with the uncommon signifier of non-Hodgkin lymphoma (NHL), said Jorge J. Castillo, MD.
Castillo is the objective manager of Bing Center for Waldenström Macroglobulinemia astatine Dana-Farber Cancer Institute. His predecessor and the existent manager of the Bing Center, Steven P. Treon, MD, PhD, led probe that resulted successful the improvement of the BTK inhibitor ibrutinib (Imbruvica) successful this diligent colonisation successful 2015.1 Over time, chemotherapy has dilatory fallen from favor.
“What we person been doing much often implicit the past 10 years is focusing connected nonchemotherapeutic approaches to dainty patients with Waldenström macroglobulinemia,” Castillo said.“We investigated the BTK pathway, the BCL2 pathway, the HCK pathway, the PI3K pathway—different pathways that we person identified and targeted successful antithetic objective trials. About 30% to 40% of patients with Waldenström macroglobulinemiacan besides person mutations successful CXCR4, truthful we developed CXCR4-targeting agents and galore different targeted therapies are coming down the road.”
Waldenström macroglobulinemia is simply a malignant upset of the bony marrow and lymphatic tissues characterized by the beingness of abnormally precocious numbers of B lymphocytes. As these cells accumulate, the assemblage produces excessive quantities of the antibody macromolecule IgM, which causes hyperviscosity and affects the travel of humor done the smaller humor vessels.
“This is simply a lymphoma defined by the beingness not lone of the malignant cells and the secretion of IgM, but besides by a mutation that is seen successful the malignant cells, specifically successful a gene, MYD88,” Castillo said. “About 90% to 95% of patients with this condition, transportation this mutation. This is an acquired mutation, which means that they didn't get it from their parents that they were not calved with these mutations, and it's lone successful the malignant cells. But nowadays, erstwhile a diligent comes to spot maine with a lymphoplasmacytic lymphoma successful the marrow and accrued serum IgM level successful the beingness of the MYD88 mutation, I'm definite that the diligent successful beforehand of maine has Waldenström macroglobulinemia.”
According to the National Organization for Rare Disorders, Waldenström macroglobulinemia affects astir 1 successful 3.4 cardinal men successful the United States and astir fractional that fig of women. Median property astatine diagnosis is 67 years, and the incidence is astir 5 per 1 cardinal radical older than the property of 50.2
Incidence grew rapidly from 1980 to 1993, with an yearly percent alteration (APC) of 14.1% (95% CI, 10.0%-18.4%) earlier stabilizing from 1993 to 2016 (APC, 0.5%; 95% CI, –0.3 to 1.3%). At the aforesaid time, investigators observed a important maturation successful 5-year endurance complaint from the 1980s to the 2010s (47.84% vs 69.41%, respectively). The median wide endurance (OS) was 96 months with a 5-year OS complaint of 64.4%.3
However, Castillo’s ain research, published successful 2014, showed that Black patients did not bask the aforesaid improvements successful endurance arsenic their White counterparts. Investigators cited some socioeconomical (ie, security coverage, attitudes toward therapy) and biologic factors (ie, Black patients person a higher hazard of processing immunoglobulin A and IgG but little hazard for IgM monoclonal paraproteinemia) arsenic causes for the disparity.4
What Does the Future of Treatment Hold?
Yin et al concluded that improvements successful supportive care, peculiarly successful the absorption of infections, cardiovascular disease, and Waldenström macroglobulinemia–related comorbidities specified arsenic hyperviscosity; person importantly reduced treatment-related mortality. Furthermore, caller attraction regimens with agents specified arsenic rituximab (Rituxan), proteasome inhibitors (PIs) similar bortezomib (Velcade) and carfilzomib (Kyprolis), BTK inhibitors, immunomodulatory drugs, and BCL-2 inhibitors person improved efficacy portion reducing toxicity successful this diligent population.3 Castillo led improvement of ixazomib (Ninlaro), an oral PI indicated for Waldenström macroglobulinemia, successful operation with dexamethasone and rituximab for Waldenström.
Even with much effectual treatments, reflection remains a viable strategy for immoderate patients. Castillo said that asymptomatic patients should not person treatment. Even though Waldenström macroglobulinemia is uncurable, diligent beingness expectancy for untreated, asymptomatic patients is akin to that of wellness race-, age- and sex-matched people.
“If you're not curing, you're not prolonging the diligent endurance successful astir cases,” helium said. “We person immoderate studies connected this—about 80% of patients volition request treatments wrong 10 years of the diagnosis, 20% tin spell beyond 10 years without being treated. One much crushed to support observing without intervention.
“But erstwhile the diligent becomes symptomatic to the constituent that the symptoms impact the patient’s activities oregon regular surviving and we bash person a precocious suspicion that the symptoms are related to the disease, past we tin treat. There are aggregate attraction options as, implicit the [past few] years, the attraction options person multiplied, and they person go safer and much effectual compared to what we had 10 years ago.”
Castillo takes large pridefulness successful starring a robust objective proceedings programme astatine Dana-Farber Cancer Institute. His radical has done extended probe into zanubrutinib (Brukinsa) and BCL-2 antagonists including venetoclax (Venclexta). Castillo’s probe with 32 patients with Waldenström macroglobulinemia, fractional of whom were antecedently exposed to BTK inhibitors demonstrated an wide effect complaint of 84% and a large effect complaint of 81%.5
Recently, investigations person turned toward immunotherapy agents. Shayna Sarosiek, MD, a elder doc astatine Dana-Farber Cancer Institute and adjunct prof of medicine astatine Harvard Medical School, is starring an ongoing signifier 2 proceedings (NCT05190705) exploring loncastuximab tesirine (Zynlonta) successful 36 patients with Waldenström macroglobulinemia. This is the archetypal clip investigators person assessed loncastuximab tesirine, an antibody-drug conjugate targeting CD19, successful Waldenström macroglobulinemia.
Castillo added that Sarosiek is besides a co-investigator for ZUMA-25 (NCT05537766), a signifier 2 proceedings exploring brexucabtagene autoleucel (Tecartus) successful adults with uncommon B-cell malignancies including Waldenström macroglobulinemia. The estimated superior completion day is November 2029.
“What’s happening each implicit the United States, successful Canada, and successful Europe is an astonishing postulation of objective trials that are combining BTK inhibitors with chemotherapy oregon different agents to effort to supply patients with faster, deeper responses, that volition hopefully past longer arsenic well. The aboriginal is looking precise optimistic successful presumption of treatments for patients with Waldenström macroglobulinemia.”
References
- U.S. FDA approves IMBRUVICA® (ibrutinib) for the attraction of Waldenström’s macroglobulinemia: archetypal FDA-approved therapy for this disease. News release. Johnson & Johnson. January 29, 2015. Accessed December 16, 2022. https://bit.ly/3YsP4NR
- National Organization for Rare Disorders. Waldenström macroglobulinemia. Accessed December 19, 2022. https://bit.ly/3HJasIN
- Yin X, Chen L, Fan F, Yan H, Zhang Y, Huang Z, Sun C, Hu Y. Trends successful incidence and mortality of Waldenström macroglobulinemia: a population-based study. Front Oncol. 2020;10:1712. doi:10.3389/fonc.2020.01712
- Castillo JJ, Olszewski AJ, Cronin AM, Hunter ZR, Treon SP. Survival trends successful Waldenstrom macroglobulinemia: an investigation of the surveillance, epidemiology and extremity results database. Blood. 2014;123(25):3999-4000. doi:10.1182/blood-2014-05-574871
- Castillo JJ, Allan JN, Siddiqi T, et al. Venetoclax successful antecedently treated Waldenström macroglobulinemia. J Clin Oncol. 2022;40(1):63-71. doi: 10.1200/JCO.21.01194
English (US)